Skip to main content

Investigators Launch Epidemiology Study in Younger Patients With NSCLC

*April 2021*

During the past decade, evidence has been building that non–small cell lung cancer (NSCLC) has a distinct clinical and genomic profile in patients 40 years and younger. Now investigators have launched the Epidemiology of Young Lung Cancer (EoYLC) study (NCT04640259) to identify risk factors that can help shed light on why lung cancer develops in the younger population.

Using an innovative web-based format, the EoYLC study will survey patients diagnosed with primary NSCLC before age 40 about their medical history, demographics, and environmental exposures, along with other epidemiological questions. Patients also will be asked to submit blood samples for genetic analysis.

The Addario Lung Cancer Medical Institute (ALCMI) is sponsoring the study in collaboration with the GO2 Foundation for Lung Cancer. Investigators are seeking to build on findings from the Genomics of Young Lung Cancer (GoYLC) study (NCT02273336), also conducted by the ALCMI in patients younger than 40 years, which found that approximately 84% of participants with lung adenocarcinoma, the most prevalent NSCLC subtype, had specific genomic mutations treatable with targeted therapies. This is a significantly higher percentage than found in the general lung cancer population.

Read more.